Business as usual for Amneal and Arrow.
Arrow Pharmaceuticals Pty Ltd has announced the acquisition of the Australian retail pharmacy business of US generics firm Amneal Pharmaceuticals, with the deal said to cement Arrow as “Australia’s fastest growing generic pharmaceutical company”.
Arrow chairman Dennis Bastas said the acquisition expands the company’s footprint and adds some “leading products and services” to Arrow’s portfolio.
“We have been fortunate to have experienced strong organic growth across our primary customer base within both our generic prescription medicines and Chemists’ Own portfolio. Bringing Amneal’s customer base into our network of supporting pharmacies further accelerates this current growth and strengthens the offering we bring to all our customers,” Bastas said.
Amneal Pharmaceuticals Australia ceo Gavin Upiter said the Arrow acquisition would bring a broader range of products to the company’s existing customers and allow Arrow to deliver new services to its current extensive user base.
More details in Monday’s issue of Pharmacy Daily.
